Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

And Then There Were 12: Follow-on Biologics Picture Coming Into Focus

Executive Summary

It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table

You may also be interested in...



Recapping The HELP Health Reform Bill, Passed By Committee July 15

The Senate Health, Education Labor and Pensions Committee's health reform bill was the first major piece of health care reform legislation to emerge from the committee stage when it was approved by the HELP panel July 15 in a party-line 13-10 vote. No Republicans on the committee supported the bill

Recapping The HELP Health Reform Bill, Passed By Committee July 15

The Senate Health, Education Labor and Pensions Committee's health reform bill was the first major piece of health care reform legislation to emerge from the committee stage when it was approved by the HELP panel July 15 in a party-line 13-10 vote. No Republicans on the committee supported the bill

Follow-on Biologics Showdown In House Set For July 17

House tri-committee bill is silent on follow-on biologics, but Rep. Anna Eshoo wants to be heard. Can the germaneness rule save Rep. Waxman from defeat?

Related Content

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel